CN110856715B - Composition, tablet and capsule containing vine tea extract - Google Patents
Composition, tablet and capsule containing vine tea extract Download PDFInfo
- Publication number
- CN110856715B CN110856715B CN201910652720.9A CN201910652720A CN110856715B CN 110856715 B CN110856715 B CN 110856715B CN 201910652720 A CN201910652720 A CN 201910652720A CN 110856715 B CN110856715 B CN 110856715B
- Authority
- CN
- China
- Prior art keywords
- vine tea
- composition
- chitosan
- standard
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 61
- 241001122767 Theaceae Species 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000002775 capsule Substances 0.000 title claims abstract description 34
- 239000003826 tablet Substances 0.000 title description 3
- 229920001661 Chitosan Polymers 0.000 claims abstract description 35
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 34
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241001018563 Nekemias grossedentata Species 0.000 abstract description 26
- 230000001953 sensory effect Effects 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 238000000605 extraction Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- -1 flavonoid compound Chemical class 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 6
- 235000013539 calcium stearate Nutrition 0.000 description 6
- 239000008116 calcium stearate Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000007902 hard capsule Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000006196 deacetylation Effects 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004649 discoloration prevention Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940025902 konjac mannan Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical group 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a composition and a tablet or capsule which contain a large amount of vine tea extract and inhibit peculiar smell (odor evaluated as malodor) of vine tea. Specifically, the composition comprises chitosan and Ampelopsis grossedentata extract, wherein each composition comprises 10-35% by mass of chitosan and 5-22% by mass of ampelopsin (ampelopsin), and the composition with the mass ratio of chitosan/ampelopsin of 0.6-3.5 is prepared and prepared into tablets or capsules.
Description
Technical Field
The present invention relates to a composition for inhibiting the odor of vine tea extract and a tablet or capsule containing the same.
Background
Ampelopsis grossedentata is a plant of Ampelopsis genus of Vitaceae family, and Chinese name is Ampelopsis grossedentata. The school name is Ampelopsisgrossedentata. Mainly distributed in Guangxi, guangdong, yunnan, guizhou, hunan, hubei, jiangxi and Fujian provinces and autonomous regions in China. People in Guangxi and Hunan provinces or municipalities in China or Yao nationalities often drink beverages made from stems and leaves of the drinks, and the drinks are also used for cold, sore throat and the like.
Various physiological activities have been found in vine tea extracts, and medical uses or health food uses containing vine tea extracts have been proposed. For example, there have been proposed uses for treating liver diseases (patent document 1), lipase inhibition (patent document 2), matrix protease inhibition (patent document 3), antibacterial (patent document 4), perfume deterioration prevention (patent document 5), pigment discoloration prevention (patent document 6), and the like.
Regarding the Ampelopsis grossedentata extract, ampelopsin, a flavonoid compound, was identified as a component responsible for the above-mentioned various actions, and a large amount of extract containing the same was obtained. The material is obtained by extracting stem and leaf of Ampelopsis grossedentata with water or aqueous alcohol, and is commercially available as concentrated paste concentrate or spray-dried or freeze-dried powder.
The vine tea extract is clear that the vine tea extract has a peculiar unpleasant odor (peculiar smell) in a preparation process for preparing capsules or tablets containing the vine tea extract. The shelf life must necessarily be shortened because of the aggravation of long-term storage.
Therefore, a preparation containing a great amount of vine tea extract, which has little off-flavor even after long-term storage and is easy to drink, is sought.
Prior art literature
Patent literature
Patent document 1: japanese patent laid-open No. 2003-026584
Patent document 2: japanese patent laid-open publication No. 2003-012536
Patent document 3: japanese patent laid-open No. 2002-173424
Patent document 4: japanese patent laid-open No. 2002-159566
Patent document 5: japanese patent application laid-open No. 2004-018756
Patent document 6: japanese patent laid-open No. 2002-065201
Disclosure of Invention
The present inventors have studied on the basis of the above-described background art, and have studied on the vine tea extract under various formulation conditions, and have found that the peculiar smell of the vine tea extract can be suppressed when a composition containing chitosan and the vine tea extract is formulated. Based on such findings, the present invention proposes a composition containing chitosan and a vine tea extract, and a tablet or capsule containing the composition.
That is, the present invention aims to provide a composition, tablet or capsule which contains a large amount of vine tea extract and suppresses the peculiar smell (odor evaluated as malodor) of vine tea.
The main constitution of the present invention is as follows.
(1) A composition contains chitosan and Ampelopsis grossedentata extract, wherein each composition contains 10-35% by mass of chitosan and 5-22% by mass of ampelopsin, and the mass ratio of chitosan/ampelopsin is 0.6-3.5.
(2) A tablet comprising the composition of (1).
(3) A capsule comprising the composition of (1).
According to the present invention, there are provided a composition, a tablet and a capsule each of which suppresses the odor of a vine tea extract. In particular, according to the present invention, long-term storage is possible, and generation of an odor from the vine tea extract is suppressed, so that it is possible to obtain a preparation which is free from contact feeling even for the aged or children and is easy to swallow.
Detailed Description
The invention relates to a composition containing chitosan and vine tea extract, and a tablet or capsule containing the composition.
One of the main constituent components of the composition of the present invention is chitosan. The chitosan is a polysaccharide mainly having a structure in which glucosamine is linked through β1,4 bonds, and may contain N-acetylglucosamine as a constituent in addition to glucosamine.
The source of the chitosan used in the present invention is not particularly limited, and for example, a crustacean shell obtained by converting calcium, protein or the like from shrimp, crab or the like; and a substance obtained by deacetylation of chitin obtained by removing cuttlefish bone or the like.
In addition, the degree of deacetylation of the chitosan used in the present invention is not particularly limited. Generally, a material having a degree of deacetylation of 50 to 100% is used. The degree of deacetylation of chitosan was measured by a colloidal titration method.
Further, the average molecular weight of the chitosan used in the present invention is not particularly limited.
The chitosan used in the present invention is preferably a powder which is used as a food material and meets the commercial specifications.
The Ampelopsis grossedentata extract can be any 1 or more than 2 extracts of leaf, stem, flower and root of Ampelopsis grossedentata. Particular preference is given to using extracts of stems or leaves.
The method of extraction from vine tea is not particularly limited. The vine tea may be used as it is or as a dried product thereof in extraction, and the dried product is preferable in terms of extraction efficiency. In addition, the extraction of the active ingredient can be performed with high extraction efficiency in a short time under stable conditions by pulverizing into particles or powder for extraction. The extraction temperature is not particularly limited, and may be appropriately set according to the particle size of the pulverized vine tea, the kind of solvent, and the like.
The kind of the solvent is not particularly limited. Lower alcohols such as water and ethanol or a mixed solvent of these are preferable. The extraction may be performed at normal temperature. It may be carried out under heating (for example, using a heated solvent such as warm water or hot water).
According to the above extraction operation, the active ingredient of the present invention can be extracted from vine tea and dissolved in a solvent. The solvent containing the extract may be used directly. It is preferably used after the usual purification treatment such as sterilization, washing, filtration, decolorization and deodorization is performed as needed. Further, the solvent was completely volatilized to form a solid (dried product). The dried product may be redissolved in an arbitrary solvent, and powdered by an operation such as spray drying. In the present invention, the above-mentioned powder is preferably used.
The extract (extract) of Ampelopsis grossedentata is commercially available from Wan Kabushiki Kaisha. The commercially available ampelopsis grossedentata extract is a powder in which extraction rate is controlled and standardized by using ampelopsin, which is one of flavonoid compounds contained in a large amount in the leaves of ampelopsis grossedentata, as an index, and the powder can be used in the present invention.
In addition, the tendril tea extract causes extremely specific undesirable odor (off-flavor) in the above-mentioned encapsulating and tableting process.
A composition containing chitosan and Ampelopsis grossedentata extract is prepared by uniformly mixing powder of chitosan and Ampelopsis grossedentata extract for inhibiting odor of Ampelopsis grossedentata. The mixing amount and mixing proportion of the powder of chitosan and vine tea extract are very important. Preferably, the chitosan is contained in an amount of 10 to 35 mass% per part of the composition. Further, ampelopsin is preferably contained in a concentration of 5 to 22% by mass per one part of the composition, and the ampelopsis grossedentata extract is preferably contained. The weight ratio of chitosan/ampelopsin is adjusted to 0.6 to 3.5.
In addition, the composition containing chitosan and vine tea extract may be mixed with various excipients such as sugar or starch, etc. for the purpose of tablet formation by a tabletting method, and may be granulated as required. By compression molding the granules or powder according to a conventional method, a tablet with suppressed odor of vine tea extract can be obtained.
When the composition is prepared into capsules, the composition is filled into hard capsules according to a conventional method to prepare the capsules. In this case, various excipients such as sugar or starch may be mixed in the preparation of the capsule, and granulation may be performed as needed to prepare granules. Capsules with suppressed off-flavors of vine tea extracts can be obtained by filling the granule or powder composition into hard capsules following conventional methods.
In the preparation, the excipient used may be cellulose, starch, lactose, maltitol, cyclodextrin, hemicellulose, guar gum, konjac mannan, alginic acid, agar, carrageenan, chitin, carboxymethyl cellulose, or polydextrose. Cellulose or starch is particularly preferred.
Further, as long as the object of the present invention is not impaired, minerals such as edible oil, calcium, iron, sodium, zinc, copper, potassium, phosphorus, magnesium, iodine, manganese, selenium, etc., fat-soluble or water-soluble vitamin groups such as vitamin a, vitamin C, vitamin D, vitamin E, vitamin K, niacin, folic acid, pantothenic acid, etc., glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, phospholipid, gum arabic, xanthan gum, tragacanth gum, locust bean gum, preservative, antioxidant, flavoring agent or flavor, flavoring agent such as sodium chloride, sodium glutamate, glycine, succinic acid, sodium lactate, etc., sour agents such as citric acid, sodium citrate, acetic acid, adipic acid, fumaric acid, malic acid, etc., low-calorie sweeteners such as aspartame, etc., may be formulated.
Examples
< Tablet >
The effect of the present invention will be described below by showing test examples using tablets of examples and comparative examples.
1. Odor assessment method
The nature of the malodour of vine tea extracts is currently not clear and therefore determines the digitisation based on sensory evaluation. Numerical values were determined by a skilled sensory evaluator by 2 comparison methods with standard, giving a score. Regarding the standard, tablets having the composition of table 1 below were prepared as the standard. In addition, the evaluation criteria are explicitly shown outside the columns of the table. The standard tablet was set to a tablet of phi 8mm, 250 mg/granule, and after mixing the raw materials, it was prepared using a single punch (manufactured by okang Tian Jinggong company) with a percussion pressure of 1000 kgf.
TABLE 1
Standard 5 | Standard 4 | Standard 3 | Standard 2 | Standard 1 | |
Vine tea extract (30% Baisu) | 0.5 | 5 | 15 | 25 | 30 |
Crystalline cellulose | 88.5 | 84 | 74 | 64 | 59 |
Starch | 10 | 10 | 10 | 10 | 10 |
Calcium stearate | 1 | 1 | 1 | 1 | 1 |
Totalizing | 100 | 100 | 100 | 100 | 100 |
Sensory evaluation was carried out with n=3
Sensory evaluation criteria:
5: odor intensity equivalent to 0.5% (standard 5) of Ampelopsis grossedentata extract
4: Odor intensity equivalent to 5% (standard 4) of Ampelopsis grossedentata extract
3: Odor intensity equivalent to 15% (standard 3) of Ampelopsis grossedentata extract
2: Odor intensity equivalent to 25% (standard 2) of Ampelopsis grossedentata extract
1: Odor intensity equivalent to 30% (standard 1) of Ampelopsis grossedentata extract
The odor intensities of criteria 5 to 1 are based on the contents shown in table 1, and correspond to the following expression in terms of sensory perception.
Standard 5: almost no odor was perceived.
Standard 4: some Xu Chouwei were felt.
Standard 3: a strong malodour is perceived but does not affect drinking.
Standard 2: a very strong odor was perceived and a conflict was perceived for drinking.
Standard 1: a bad smell was perceived.
2. Preparation and evaluation of tablets of examples 1 to 6 and comparative examples 1 to 6
According to the formulation of Table 2, the raw materials were mixed and then a tablet having a diameter of 8mm and a diameter of 250 mg/granule was produced by a single punch tablet press (manufactured by Gang Tian Jinggong Co.). After placing the 20 tablets in an aluminum bag and storing them in an oven at 40 ℃ and 75% RH for 2 weeks, the odor generated at the time of unsealing was evaluated by 3 sensory panelists who had been trained in the professionals. In addition, 5 tablets prepared as described above were used as standards, and the identity was judged by 2 comparison methods.
The evaluation is determined, for example, to be 3 if the test article is an unpleasant odor equivalent to standard 3. In addition, the sensory test results were averaged over 3 scores. The results are shown in the last row of table 2.
The unpleasant odor judged to be above the sensory evaluation average value 4 was reduced.
TABLE 2
< Formulation (%) >
The extract of vine tea (30% Baisu): pharmaceutical Co Ltd
Chitosan: "Chitosamine" manufactured by FOOD TECHNO Co., ltd "
Crystalline cellulose: xudi chemical Co., ltd., "CEOLUS UF-F702"
Starch: xudi chemical Co., ltd., "PCS-50"
Calcium stearate: calcium stearate manufactured by Sakai chemical industry Co., ltd "
From the experimental results using the tablets of examples 1 to 6 and comparative examples 1 to 6, it was revealed that the blending of chitosan was effective for suppressing the specific odor derived from the vine tea extract in the tablets containing the vine tea extract. In addition, in the composition before tabletting containing chitosan and vine tea extract, if each composition contains 5-22 mass% of ampelopsin and 10-35 mass% of chitosan, and the mass ratio of chitosan/ampelopsin is adjusted to 0.6-3.5, tablets which can not feel specific odor from vine tea can be obtained.
< Capsule >
The effect of the present invention will be described below by showing test examples using capsules of examples and comparative examples.
1. Odor assessment method
As with the tablet test, scores were given by a expert sensory evaluator judged by 2 comparison methods with the standard. Regarding the standard, capsules having the composition shown in table 3 below were prepared and used as the standard. In addition, the evaluation criteria are explicitly shown outside the columns of the table.
After mixing the raw materials, a hard capsule (capsule shell is manufactured by capsule corporation) of capsule size No.2 was prepared using a hard capsule filler ("Profill 100" manufactured by capsule corporation).
TABLE 3
Standard 5 | Standard 4 | Standard 3 | Standard 2 | Standard 1 | |
Vine tea extract (30% Baisu) | 0.5 | 5 | 15 | 25 | 30 |
Maltitol | 98.5 | 94 | 84 | 74 | 69 |
Calcium stearate | 1 | 1 | 1 | 1 | 1 |
Totalizing | 100 | 100 | 100 | 100 | 100 |
Sensory evaluation was carried out with n=3
Sensory evaluation criteria:
5: odor intensity equivalent to 0.5% (standard 5) of Ampelopsis grossedentata extract
4: Odor intensity equivalent to 5% (standard 4) of Ampelopsis grossedentata extract
3: Odor intensity equivalent to 15% (standard 3) of Ampelopsis grossedentata extract
2: Odor intensity equivalent to 25% (standard 2) of Ampelopsis grossedentata extract
1: Odor intensity equivalent to 30% (standard 1) of Ampelopsis grossedentata extract
The odor intensities of criteria 5 to 1 were set as described in the above table 3, and they were equivalent to the following expression in terms of sensory properties.
Standard 5: almost no odor was perceived.
Standard 4: some Xu Chouwei were felt.
Standard 3: a strong malodour is perceived but does not affect drinking.
Standard 2: a very strong odor was perceived and a conflict was perceived for drinking.
Standard 1: a bad smell was perceived.
2. Preparation and evaluation of capsules of examples 7 to 12 and comparative examples 7 to 12
According to the formulation of table 4, the raw materials were mixed, and a hard capsule (capsule shell, manufactured by capsule corporation) of capsule size No. 2 was prepared using a hard capsule filler ("Profill" manufactured by capsule corporation) in the same manner as the standard. After the capsule 20 pellets were sealed in an aluminum bag and stored in an incubator at 40 ℃ 75% rh for 2 weeks, the odor generated at the time of unsealing was evaluated by 3 sensory panelists who had been subjected to specialized training.
In addition, identity was judged by 2 comparison methods with the 5 standard capsules prepared above.
The evaluation is determined, for example, to be 3 if the test article is an unpleasant odor equivalent to standard 3. In addition, the sensory test results were averaged over 3 scores. The results are shown in the last row of table 4.
The unpleasant odor judged to be above the sensory evaluation average value 4 was reduced.
TABLE 4
< Formulation (%) >
The extract of vine tea (30% Baisu): pharmaceutical Co Ltd
Chitosan: "Chitosamine" manufactured by FOOD TECHNO Co., ltd "
Maltitol: "Amalty MR-50" manufactured by Mitsubishi business FOOD TECHNO Co "
Calcium stearate: calcium stearate manufactured by Sakai chemical industry Co., ltd "
From the experimental results using the capsules of examples 7 to 12 and comparative examples 7 to 12, it was revealed that the blending of chitosan was effective in suppressing the specific odor derived from the vine tea extract in the capsules containing the vine tea extract. In addition, in the composition before filling the capsule containing chitosan and ampelopsin, if each part of the composition contains 5 to 22 mass percent of ampelopsin and 10 to 35 mass percent of chitosan, and the mass ratio of chitosan/ampelopsin is adjusted to be 0.6 to 3.5, the capsule which can not feel the specific odor from the ampelopsin can be obtained.
Claims (3)
1. An oral composition comprising chitosan and a vine tea extract, characterized in that each part of the composition comprises 30-70% by mass of vine tea extract and 10-35% by mass of chitosan; the content of ampelopsin from vine tea extract is 5-22% by mass, and the mass ratio of chitosan/ampelopsin from vine tea extract is 0.6-3.5.
2. A tablet comprising the oral composition of claim 1.
3. A capsule comprising the oral composition of claim 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018157129A JP7156861B2 (en) | 2018-08-24 | 2018-08-24 | Composition, tablet, capsule containing wisteria tea extract |
JP2018-157129 | 2018-08-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110856715A CN110856715A (en) | 2020-03-03 |
CN110856715B true CN110856715B (en) | 2024-09-03 |
Family
ID=69623794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910652720.9A Active CN110856715B (en) | 2018-08-24 | 2019-07-19 | Composition, tablet and capsule containing vine tea extract |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP7156861B2 (en) |
CN (1) | CN110856715B (en) |
TW (1) | TWI819039B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116808115A (en) * | 2023-05-31 | 2023-09-29 | 姚美华 | Application of ampelopsis grossedentata extract in preparation of antibacterial and/or repairing products |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772586A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Preparation with hangover alleviating and liver protection functions and preparation method thereof |
CN102771593A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002370962A (en) | 2001-06-13 | 2002-12-24 | Maruzen Pharmaceut Co Ltd | Bleaching preparation and cosmetic for preventing and improving aging of skin |
JP5004314B2 (en) | 2001-06-27 | 2012-08-22 | 丸善製薬株式会社 | Lipase inhibitor |
JP2009013073A (en) | 2007-06-29 | 2009-01-22 | Kumamoto Prefecture | Fine chitosan particles |
-
2018
- 2018-08-24 JP JP2018157129A patent/JP7156861B2/en active Active
-
2019
- 2019-07-19 CN CN201910652720.9A patent/CN110856715B/en active Active
- 2019-07-24 TW TW108126159A patent/TWI819039B/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772586A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Preparation with hangover alleviating and liver protection functions and preparation method thereof |
CN102771593A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method |
Non-Patent Citations (1)
Title |
---|
关志宇.药物制剂辅料与包装材料.中国医药科技出版社,2017,(第第1版版),143-144页. * |
Also Published As
Publication number | Publication date |
---|---|
TW202023597A (en) | 2020-07-01 |
JP2020029437A (en) | 2020-02-27 |
JP7156861B2 (en) | 2022-10-19 |
TWI819039B (en) | 2023-10-21 |
CN110856715A (en) | 2020-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201711694A (en) | Method for producing processed ginger product, processed ginger product and method for enriching shogaols | |
CN110856715B (en) | Composition, tablet and capsule containing vine tea extract | |
KR101841950B1 (en) | Method for reducing unpleasant taste | |
JP2005237291A (en) | Health food | |
KR20180005938A (en) | High condensed onion composition and the method for preparing thereof | |
JP6584794B2 (en) | Food in containers containing acetic acid bacteria or pulverized products thereof | |
KR102108686B1 (en) | Onion Coat Feed composition Using An Enzyme With Stevia Extract And Method thereof | |
JP6152251B2 (en) | Spring turmeric component-containing beverage and method for adjusting flavor with spring turmeric component | |
KR20170136785A (en) | Composition for enhancing the bioavailability of fat-soluble vitamins | |
JP5691638B2 (en) | Propolis composition and method for producing the same | |
KR101773251B1 (en) | The manufacturing method of making healthcare compositions comprising fermented Cudrania tricuspidata extracts and herbal medicines Abalone extracts | |
JP4315753B2 (en) | Food material and manufacturing method thereof | |
KR101617577B1 (en) | Composition containing plant extracts for removal of heavy metals and detoxification effect | |
JP2005237290A (en) | Health food | |
JP6316565B2 (en) | Composition comprising turmeric extract and organic acid salt | |
CA3122201C (en) | Kombucha natural health products | |
KR101433572B1 (en) | Method for preparation of extract of bean sprouts | |
JP5967900B2 (en) | Taste improving agent | |
WO2017068805A1 (en) | Saliva secretion promoter, and oral composition and drinkable composition containing same | |
CN106721800A (en) | A kind of formula of lotus leaf tribute chrysanthemum functional beverage and preparation method thereof | |
JP2006306840A (en) | Anti-obesity agent and food containing the anti-obesity agent | |
WO2023090075A1 (en) | Oral composition containing processed mulberry leaf | |
JP6371627B2 (en) | Powdered saliva secretion promoter | |
JP2005237292A (en) | Health food | |
JP2022050660A (en) | Blood cholesterol rise inhibitory composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40022936 Country of ref document: HK |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |